Crown Bioscience International announces Agreement and Plan of Merger with JSR Corporation
SAN DIEGO, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience International ("CrownBio") (TWSE:ticker 6554) on December 19, 2017 has entered into the Agreement and Plan of Merger (the "Merger Agreement") with JSR Corporation ("JSR") and Gallo Merger Sub Corp, pursuant to which, and subject to the conditions precedent contained therein, Gallo Merger Sub Corp will merge with and into CrownBio with CrownBio continuing as the surviving company and a wholly-owned subsidiary of Parent (the "Merger"). The Merger and the Merger Agreement were unanimously approved by CrownBio's Board of Directors on December 19, 2017. Pursuant to the Merger Agreement, each of CrownBio's ordinary shares issued and outstanding immediately prior to the effective time of the Merger will be cancelled and cease to exist in exchange for the right to receive NTD 75.00 per share in cash without interest. The per share purchase price of NTD 75.00 represents a 104.6% premium to the 30-day volume weighted average price (as of December 19, 2017) of CrownBio's ordinary shares on the Taipei Exchange. Upon the completion of the merger, CrownBio will become the wholly owned subsidiary of JSR, be delisted from the Taipei Exchange and revoke its status of public issuing company.
CrownBio will hold an extraordinary general meeting of shareholders on February 8, 2018 to discuss the proposed merger. The closing of the proposed merger is subject to customary conditions precedent, including but not limited to the approval of the shareholders meeting and the regulators. The completion of the merger is not subject to a financing contingency. The Merger is expected to close before the end of the second quarter of 2018.
JSR is a leading provider of petrochemical, fine chemical, life sciences and lithium ion capacitor products in Japan and internationally. JSR's Life Sciences division supplies in-vitro diagnostics and reagents used to support medical research and diagnosis, bioprocess materials used in personalized and biotechnology-based medicine and medical polymers used in a wide range of medical supplies globally. The proposed transaction recognizes the value created by CrownBio and provides CrownBio shareholders with liquidity at a premium price. For CrownBio, its employees and customers, the transaction strengthens CrownBio's leading translational medicine platform supporting drug target validation, efficacy testing and patient response characterization and enables the seamless delivery of services from drug discovery through manufacturing while creating new opportunities to contribute to the improvement of the drug development process.
Jefferies Hong Kong Limited acted as exclusive financial advisor to CrownBio, and Cooley LLP, Lee and Li, Attorneys-at-Law and Conyers Dill & Pearman acted as legal advisors to CrownBio.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. marketing@CrownBioscience.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
eGain to exhibit at Call Centre World 2018 in Berlin23.1.2018 12:30 | Pressemelding
Company will join forces with Cisco to showcase knowledge-infused, AI-guided omnichannel customer engagement at Europe's premier call centre conference SUNNYVALE, Calif. and NEWBURY, U.K., Jan. 23, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud customer engagement solutions, today announced that the company will showcase its award-winning digital engagement suite for the Cisco contact centre infrastructure-eGain Solve(TM) for Cisco Unified CCE(TM)-at CCW 2018 in Berlin, scheduled for February 26th through March 1st , 2018. Proven in world-class deployments, eGain Solve suite helps companies simultaneously elevate the customer experience (CX), business experience (BX), and agent experience (AX) to make digital transformation of experiences (DX) easy and successful. The solution dramatically improves metrics such as NPS (Net Promoter Score), CSAT (Customer Satisfaction), FCR (First-Contact Resolution), AHT (Average Handle Time), speed to agent competency, tra
Quinta do Lago: A resort that delivers year-round ROI23.1.2018 12:10 | Pressemelding
LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- A holiday home is not only somewhere to create treasured memories with family and friends, it can also represent a solid business investment. Accessibility, amenities, seasonal consistency and security are all likely to be key considerations when searching for a potential location, and Quinta do Lago scores highly across the board. Located just to the west of Faro Airport, the picturesque resort is part of the Algarve's Golden Triangle and easily accessible from most UK airports, as well as major European cities such as Paris, Madrid and Frankfurt. Accessibility is essential if holiday homes are to provide year-round return on investment (ROI), and Quinta do Lago is capable of attracting weekend holidaymakers and longer-term travellers alike. Fantastic leisure facilities ensure that the resort delivers year-round appeal. Golf, wellness services, award-winning restaurants and a multi-sports hub provide Quinta do Lago with seasonal consistency. F
AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia23.1.2018 04:44 | Pressemelding
TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, an investigational gene therapy for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease. The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan. AnGes anticipates being granted conditional approval under the regulatory scheme of "Approval with Conditions and Time Limit" for regenerative medicines. The review process is expected to take approximately one year. HGF plasmid has the potential to be one of the first gene therapy products to be approved for a non-genetic disease with chronic conditions. AnGes grants to Mitsubishi Tan
SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line23.1.2018 00:59 | Pressemelding
Boungou 80% Complete - Continues on Time, on Budget MONTREAL, Jan. 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports 2017 production of 206,400 ounces at an all-in sustaining cost of $943 per ounce. As a result, the Corporation has beat its revised production and met its cost guidance for the year. Mana In the fourth quarter, Mana produced 49,500 ounces of gold at a total cash cost1 of $667 per ounce and all-in sustaining cost2 of $987 per ounce Annual production of 206,400 ounces, slightly ahead of 2017 guidance of 190,000 to 205,000 ounces Total cash cost1 for 2017 of $655 per ounce All-in sustaining cost2 for 2017 of $943 per ounce, in line with guidance of $920 to $960 per ounce Gold sales of 205,300 ounces generated 2017 revenues of $259 million ($1,261 per ounce) Mining Operations Mana, Burkina Faso Three-month period Year ended December 31, ended December 31, 2017 2016 Variation 2017 2016 Variation Tonnes processed 653,500 714,200 (8%) 2,739,900 2,753,300 - He
Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30 | Pressemelding
VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti
Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54 | Pressemelding
PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 firstname.lastname@example.org http://www.rns.com This announ
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom